RemovedRisk Factors
“anti-ESG” policies, legislation, or initiatives or issuing related legal opinions, as well as executive actions in response to ESG-related initiatives in the private sector. Such anti-ESG-related policies, legislation, initiatives, litigation, legal opinions, and scrutiny could result in additional compliance obligations, becoming the subject of investigations and enforcement actions, or sustaining reputational harm.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedRisk Factors
Senate For example, on February 3, 2026, the Consolidated Appropriations Act of 2026 was signed into law and House of Representatives proposed a number of bills includes PBM reforms that would, among other things, require PBMs to submit disclose information on their costs, fees and rebates; require 100% of the rebates to be passed on to consumers; and/or and impose rebates other disclosure, reporting and audit requirements on manufacturers that choose to increase their drug prices at a rate that exceeds the inflation rate. PBMs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, in recent years, “anti-ESG” sentiment has gained momentum across the U.S., with several states, Congress, and most recently, the new U.S. presidential administration proposing or enacting “anti-ESG” policies, legislation, or initiatives or issuing related legal opinions, as well as executive actions in response to ESG-related initiatives in the private sector.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Such changes may also impact our ability to offer our products in the same manner to our clients, which may require us to change, reduce, or terminate portions of our business, disqualify us from serving clients in certain states or clients that do business with government entities, or to refund some or all of our service fees or otherwise compensate our clients.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In June 2022, July 2024, the FTC announced an inquiry into the role of released its interim staff report on PBMs and stated its intent to closely scrutinize the impact of PBM rebates and fees on patients and payers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although President Biden issued executive orders and federal agencies have issued guidance intended to protect access to reproductive healthcare services, the The enactment of certain state laws restricting abortion care and other changes in laws, or in interpretation of laws through court decisions, affecting fertility benefits may conflict with, and ultimately limit, the covered benefits offered by a company to its employees and the types of fertility treatment services available at provider clinics.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
A number of these proposed laws would require In certain states, PBMs are required to submit annual file transparency reports or otherwise disclose contractual arrangements with health plans or health insurance issuers or allow and regulators have begun to conduct audits of PBM operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the information we publish is considered untrue, we may be subject to claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences, including, costs of defending against litigation or settling claims and loss of existing and future clients.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have also expanded our offerings to include preconception, maternity pregnancy and postpartum and postpartum, menopause and midlife care care, benefit and leave navigation and parent and child wellbeing solutions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Separately, although ERISA generally preempts state laws that would otherwise apply to ERISA plans, the recent Supreme Court ruling in Rutledge v. rulings continue to clarify ERISA preemption as it relates to PBMs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Revenue Our future revenue and our client base may not grow at the same rates they historically have, or they may decline in the future. at all.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Negative conditions in the general economy in the United States and elsewhere, including conditions resulting from changes in gross domestic product growth, financial and credit market fluctuations, inflation, consumer confidence, international trade relations, tariffs, export controls and other trade barriers, global trade wars or domestic preferences, geopolitical conflict, political turmoil, natural catastrophes, epidemics, pandemics or outbreaks of contagious diseases, warfare and terrorist attacks, could cause a decrease in business investments, including spending on employee benefits, and negatively affect the growth of our business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
For the year ended December 31, 2024, one 2025, none of our clients accounted for 12% more than 10% of our total revenue (the "Client"). revenue.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We continue to expand our women's health and family building solutions to include pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. While these offerings represent strategic areas of investment, they were not a significant portion of our revenue for the years ended December 31, 2025 and 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
On July 1, 2025, we entered into a revolving credit facility (the “Facility”) pursuant to a Credit Agreement (the “Credit Agreement”) with the lenders and issuing banks, party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, and swing line lender. The Credit Agreement makes available a maximum aggregate amount of $200 million, subject to customary borrowing conditions, until its maturity on July 1, 2030. We are in compliance with all financial covenants under the Credit Agreement as of December 31, 2025. As of the date of this filing, no amounts were drawn under the Facility. Refer to Note 9 to the Consolidated Financial Statements included in this Annual Report on Form 10-K for additional information.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, our Board of Directors authorized a share repurchase program of up to $200 million in shares of common stock (the “November 2025 share repurchase program”). Repurchases under the November 2025 share repurchase program may be made in the form of open market repurchases, including through plans complying with Rule 10b5-1 under the Exchange Act, depending on stock price, market conditions, and other factors, as determined by the Company. There can be no assurance as to the total number of shares that will be repurchased by the Company under the November 2025 share repurchase program.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
formulary management, drug utilization review and cost containment services and other care management services.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
personnel costs, including stock-based compensation expense, and other costs necessary to deliver our care management services will continue to grow as we continue to add clients and their associated members.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedMD&A
Net cash used in financing activities was $309.9 $99.4 million for the year ended December 31, 2024, 2025, consisting of $300.3 $81.7 million of repurchases of common stock under the 2024 Share Repurchase Programs, November 2025 share repurchase program, inclusive of $0.4 $0.1 million in trading fees and fees, payments of $12.0 $15.8 million for employee taxes related to the net settlement of equity awards, and $3.1 million of issuance costs related to the Facility, partially offset by $1.1 million in proceeds from stock option exercises and $1.3 million in proceeds from contributions to our employee stock purchase plan. plan and $0.1 million in proceeds from stock option exercises.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was primarily due to a $6.0 $16.5 million increase in personnel-related costs costs, which included an increase of $5.0 million in stock-based compensation expense, attributable to incremental head count, count and executive severance costs, a $4.1 million increase in bad debt expense driven by our revenue growth, and a $2.3 $4.5 million net increase in other related general and administrative expenses, partially offset by a $3.5 million decrease in bad debt expense. expenses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 (in thousands) Cash Net cash provided by operating activities $ 210,192 $ 179,105 $ 188,814 Cash Net cash (used in) provided by (used in) investing activities (159,013) 195,792 (200,525) Cash Net cash used in financing activities (99,362) (309,880) (11,072) Effect of exchange rate changes on cash, cash equivalents, and restricted cash equivalents $ 1 $ 62 1 Net (decrease) increase (decrease) in cash, cash equivalents, and restricted cash equivalents $ (48,121) $ 65,018 $ (22,782)
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
(3)Includes approximately 300,000 members from a single client who are not reflected in utilization as a result of the client's chosen benefit design. 2025 excludes the limited number of members who were eligible to use the benefit under the extended transition of care agreement that ended June 30, 2025 with the large client who did not renew its service agreement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Interest and other income, net increased decreased by $7.2 $5.6 million or 36%, for the year ended December 31, 2024 2025 compared to the year ended December 31, 2023, primarily due to increases 2024, as higher interest income was more than offset by a decrease in investment income and an increase in interest income. expense.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Net cash provided by operating activities was $179.1 $210.2 million for the year ended December 31, 2024, 2025, primarily consisting of net income of $54.3 $58.5 million adjusted for certain non-cash items, which included $128.1 includes $131.9 million of stock-based compensation expense, $16.4 $20.5 million of bad debt expense, $10.5 $8.1 million of deferred tax benefit, $3.2 $4.9 million of depreciation and amortization, $2.1 amortization expense, $0.9 million of net accretion of discounts on marketable securities, $0.4 million of non-cash interest expense, and $1.4 $0.1 million of loss on disposal of property and equipment.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
This increase in cost of services was also attributable to an increase in personnel-related costs primarily due as higher costs attributable to incremental headcount as well as an $2.3 million increase head count were partially offset by a decrease in stock-based compensation expense. expense of $1.5 million.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
For the year ended December 31, 2024, 2025, we recorded a provision for income taxes of $28.9 $36.9 million, as compared to a provision for income taxes of $8.7 $28.9 million for the year ended December 31, 2023, 2024, primarily due to a higher operating profit as well as and a decrease in tax benefits for equity compensation. compensation in the current year period.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
In February 2022, we entered into a lease agreement for leases commencing in February 2023 and March 2025 for additional space in our corporate offices in New York, New York, consisting of a 24,099 square foot office and a 21,262 square foot office, and also for continued occupancy of the 25,212 square foot office after the expiration of the current sublease. respectively.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
A discussion of the fiscal year ended December 31, 2023 2024 as compared to the year ended December 31, 2022 2023 has been reported previously in our Annual Report on Form 10-K for the year ended December 31, 2023 2024, which was filed with the SEC on February 29, 2024 March 3, 2025 (File No. 001-39100) under the heading “Management's Discussion and Analysis of Financial Condition and Results of Operations - Comparison of Years Ended December 31, 2023 2024 and 2022.” 2023.”
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
This increase was primarily due to a $3.5 $5.8 million increase in personnel-related costs attributable to incremental head count which included an increase in stock-based compensation expense, as well as expense of $0.2 million, and a $1.0 $2.4 million increase in other related sales and marketing expenses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, we repurchased a total of 12,382,193 3,301,596 shares of common stock under the 2024 Share Repurchase Programs November 2025 share repurchase program at an average price per share of $24.22 $25.31 and a total cost of $300.3 $83.6 million, inclusive of $0.4 $0.1 million in trading fees.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
We are a benefits management company specializing in fertility, family building, and women's health benefits solutions primarily in the United States.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Interest and other income, net primarily includes interest income and expense, expense as well as investment income and losses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
We believe there is sufficient positive evidence to conclude that it is more likely than not not, that substantially all the net deferred tax assets were realizable as of December 31, 2024. 2025.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new